Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CPA1 | P15085 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122899 | 0.81 | GRIK1 (0.35) | CYP2C19GRIK1GRIK2ALDH1A1LMNA | |
| SCHEMBL262483 | 0.79 | POLB (0.43) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL11801523 | 0.79 | POLB (0.43) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL21828164 | 0.76 | CYP3A4 (0.41) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL14561060 | 0.76 | POLB (0.41) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL194844 | 0.76 | POLB (0.42) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 | |
| SCHEMBL2364326 | 0.75 | TSHR (0.32) | TSHR | |
| SCHEMBL9723381 | 0.75 | TSHR (0.39) | POLBCYP2C19CYP3A4CYP2C9GAA | |
| SCHEMBL20201445 | 0.75 | GRIK1 (0.38) | CYP2C19GRIK1GRIK2MAPTCPA1 | |
| SCHEMBL30008276 | 0.74 | POLB (0.40) | POLBCYP2C19CYP3A4CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0259227-B1 | BENZHYDRYLOXYETHYL PIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Société anonyme: LES LABORATOIRES MERAM (FR) | 1991-12-27 | — | — | EP | claimed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| US-7250402-B2 | Avermectin derivatives | THE KITASATO INSTITUTE (JP) | 2007-07-31 | — | — | US | disclosed |
| US-20050148520-A1 | Avermectin derivatives | KITASATO INSTITUTE (JP) | 2005-07-07 | — | — | US | disclosed |
| US-20040214232-A1 | Generation of skeletal diversity within a combinatorial library | HOWARD HUGHES MEDICAL INSTITUTE | 2004-10-28 | — | — | US | disclosed |
| US-20040087519-A1 | Avermectin derivatives | KITASATO INSTITUTE, THE (JP) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087519-A1 | Avermectin derivatives | SUV39H1, ZC3HAV1L, ZC3HAV1 | POLB 4407/4885CYP2C19 1468/4885CYP3A4 1054/4885 |
| US-20050148520-A1 | Avermectin derivatives | DOT1L, ARG1, CARM1 | POLB 3797/4885CYP2C19 1395/4885CYP3A4 996/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | POLB 2945/4885CYP2C19 1331/4885CYP3A4 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.